These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1376 related items for PubMed ID: 24947719

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
    Kohli P, Udell JA, Murphy SA, Cannon CP, Antman EM, Braunwald E, Wiviott SD.
    J Am Coll Cardiol; 2014 Jan 28; 63(3):225-32. PubMed ID: 24140678
    [Abstract] [Full Text] [Related]

  • 3. Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention: the ETAMI trial (early thienopyridine treatment to improve primary PCI in patients with acute myocardial infarction).
    Zeymer U, Mochmann HC, Mark B, Arntz HR, Thiele H, Diller F, Montalescot G, Zahn R.
    JACC Cardiovasc Interv; 2015 Jan 28; 8(1 Pt B):147-154. PubMed ID: 25616919
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).
    Wiviott SD, Antman EM, Gibson CM, Montalescot G, Riesmeyer J, Weerakkody G, Winters KJ, Warmke JW, McCabe CH, Braunwald E, TRITON-TIMI 38 Investigators.
    Am Heart J; 2006 Oct 28; 152(4):627-35. PubMed ID: 16996826
    [Abstract] [Full Text] [Related]

  • 5. Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
    Ojeifo O, Wiviott SD, Antman EM, Murphy SA, Udell JA, Bates ER, Mega JL, Sabatine MS, O'Donoghue ML.
    JACC Cardiovasc Interv; 2013 Dec 28; 6(12):1275-81. PubMed ID: 24239201
    [Abstract] [Full Text] [Related]

  • 6. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38.
    Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW, Goodman SG, Corbalan R, Purdy DA, Murphy SA, McCabe CH, Antman EM, TRITON-TIMI 38 Investigators.
    Circulation; 2008 Oct 14; 118(16):1626-36. PubMed ID: 18757948
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction.
    Morrow DA, Wiviott SD, White HD, Nicolau JC, Bramucci E, Murphy SA, Bonaca MP, Ruff CT, Scirica BM, McCabe CH, Antman EM, Braunwald E.
    Circulation; 2009 Jun 02; 119(21):2758-64. PubMed ID: 19451347
    [Abstract] [Full Text] [Related]

  • 9. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
    O'Donoghue M, Antman EM, Braunwald E, Murphy SA, Steg PG, Finkelstein A, Penny WF, Fridrich V, McCabe CH, Sabatine MS, Wiviott SD.
    J Am Coll Cardiol; 2009 Aug 18; 54(8):678-85. PubMed ID: 19679245
    [Abstract] [Full Text] [Related]

  • 10. Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial.
    De Servi S, Goedicke J, Schirmer A, Widimsky P.
    Eur Heart J Acute Cardiovasc Care; 2014 Dec 18; 3(4):363-72. PubMed ID: 24818952
    [Abstract] [Full Text] [Related]

  • 11. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
    Aradi D, Tornyos A, Pintér T, Vorobcsuk A, Kónyi A, Faluközy J, Veress G, Magyari B, Horváth IG, Komócsi A.
    J Am Coll Cardiol; 2014 Mar 25; 63(11):1061-70. PubMed ID: 24486281
    [Abstract] [Full Text] [Related]

  • 12. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy.
    Pride YB, Wiviott SD, Buros JL, Zorkun C, Tariq MU, Antman EM, Braunwald E, Gibson CM, TIMI Study Group.
    Am Heart J; 2009 Sep 25; 158(3):e21-6. PubMed ID: 19699846
    [Abstract] [Full Text] [Related]

  • 13. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.
    Antman EM, Wiviott SD, Murphy SA, Voitk J, Hasin Y, Widimsky P, Chandna H, Macias W, McCabe CH, Braunwald E.
    J Am Coll Cardiol; 2008 May 27; 51(21):2028-33. PubMed ID: 18498956
    [Abstract] [Full Text] [Related]

  • 14. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM, TRITON-TIMI 38 investigators.
    Lancet; 2009 Feb 28; 373(9665):723-31. PubMed ID: 19249633
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38.
    Mahoney EM, Wang K, Arnold SV, Proskorovsky I, Wiviott S, Antman E, Braunwald E, Cohen DJ.
    Circulation; 2010 Jan 05; 121(1):71-9. PubMed ID: 20026770
    [Abstract] [Full Text] [Related]

  • 16. Timing of thienopyridine loading and outcomes in the TRITON trial: the FDA Prasugrel Action Package outlook.
    Serebruany VL.
    Cardiovasc Revasc Med; 2011 Jan 05; 12(2):94-8. PubMed ID: 21421187
    [Abstract] [Full Text] [Related]

  • 17. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
    Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E, PRINCIPLE-TIMI 44 Investigators.
    Circulation; 2007 Dec 18; 116(25):2923-32. PubMed ID: 18056526
    [Abstract] [Full Text] [Related]

  • 18. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial.
    Valgimigli M, Tebaldi M, Campo G, Gambetti S, Bristot L, Monti M, Parrinello G, Ferrari R, FABOLUS PRO Investigators.
    JACC Cardiovasc Interv; 2012 Mar 18; 5(3):268-77. PubMed ID: 22440491
    [Abstract] [Full Text] [Related]

  • 19. Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study.
    Gibson CM, Murphy SA, Pride YB, Kirtane AJ, Aroesty JM, Stein EB, Ciaglo LN, Southard MC, Sabatine MS, Cannon CP, Braunwald E, TIMI Study Group.
    Am Heart J; 2008 Jan 18; 155(1):133-9. PubMed ID: 18082504
    [Abstract] [Full Text] [Related]

  • 20. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial.
    Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, Carney RJ, Lazzam C, McKay RG, McCabe CH, Braunwald E, JUMBO-TIMI 26 Investigators.
    Circulation; 2005 Jun 28; 111(25):3366-73. PubMed ID: 15967851
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 69.